Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USL311 + lomustine
- Development stage
- Discontinued
- Lead developer
- Proximagen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
USL311 + lomustine is a combination regimen consisting of USL311, a small molecule antagonist of the CXCR4 receptor, and lomustine, a cytotoxic nitrosourea alkylating agent. USL311 targets the CXCR4 receptor, inhibiting migration, self-renewal, and survival of cancer stem cells, potentially sensitizing them to chemotherapy via inhibition of autophagy. Lomustine, primarily used as an oral chemotherapeutic agent in brain tumors, functions through alkylation of DNA, leading to cytotoxicity. This combination has been evaluated in Phase 1/2 clinical trials for advanced solid tumors and relapsed/recurrent glioblastoma multiforme (GBM), with USL311 hypothesized to enhance the efficacy of lomustine by overcoming tumor resistance linked to cancer stem cells[1][2][3][5].
- Other names
- CCNUUSL311 + CCNU
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)DNANeuraminidase
Beyond the preview
Go deeper on USL311 + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USL311 + lomustine.